
The Model
The hub — SKIA itself — sources and acquires overlooked assets, funds the initial work to establish a strategy, and then seeds a new portfolio company or strengthens an existing one.
Each portfolio company carries a single therapeutic-area focus and is either founded by SKIA around a foundational asset or brought into the fold through recapitalization or acquisition.
Ensures Diversification in Two Dimensions

Vertically
Each company builds depth over time through pipeline expansion and lifecycle management
Horizontally
The portfolio spans multiple therapeutic areas, so no single scientific venture defines the platform
Portfolio Companies Are Established Around Foundational Assets
Game-Changing Biology
Companies will be built around a foundational asset that has the potential to address a major "white space" disease area or is meaningfully clinically superior to existing therapies.
Novel biology that is unlikley to translate into meaningful clinical benefits would be out of scope.
Biology that is linear is highly preferred.
Existing Proof of Concept
There needs to be some data that links the asset to the desired outcomes, ideally existing human data. In some cases, pre-clinical to human translational work may suffice.
Pure pre-clinical programs are out of scope.
Near-Term Inflection
Next clinical data point should be achievable within a 24-36 month window.
Line-of-Sight to Liquidity
The goal is to create companies with foundational assets that can generate data that is compelling enough to take the portfolio companies public.
Portfolio Companies Evolve From Incubation to Independence

Value creation follows the structure
SKIA owns significant stakes in each portfolio company. As portfolio companies are priced, through private financings or accessing the public markets, value accrues back to SKIA.
Asset Identification and Selection Powered by Proprietary AI Model
SKIA
